S&P Futures
4,303.75 -4.00 (-0.09%) Dow Futures
34,108.00 -10.00 (-0.03%) Nasdaq Futures
13,623.25 -35.00 (-0.26%) Russell 2000 Futures
2,023.40 +0.10 (+0.00%) Crude Oil
87.13 +0.60 (+0.69%) Gold
1,789.50 -0.20 (-0.01%)
Larkspur Health Acquisition Corp. (LSPR)
Chart Events
Performance Outlook
| Previous Close | 9.99 |
| Open | 10.00 |
| Bid | 9.88 x 800 |
| Ask | 15.98 x 1000 |
| Day's Range | 9.99 - 9.99 |
| 52 Week Range | 9.80 - 10.30 |
| Volume | |
| Avg. Volume | 9,774 |
| Market Cap | 100.292M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for LSPR
Related Research
- Larkspur Health Acquisition CorDaily – Vickers Top Buyers & Sellers for 01/26/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 months agoArgus Research
- PR Newswire
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics
Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company, and ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address unmet medical needs in the areas of renal and inflammatory diseases, are pleased to announce that Larkspur has filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statem
- Perella Weinberg Partners Announces Effectiveness of Registration Statement for Its Exchange Offer and Consent Solicitation Relating to Its WarrantsGlobeNewswire
- CleanTech Acquisition Corp. Announces Effectiveness of Registration Statement and Date for Special Meeting to Approve Business Combination with Nauticus Robotics, Inc.GlobeNewswire
- PR Newswire
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper
ZyVersa Therapeutics, Inc., (ZyVersa) a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, and Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company are pleased to announce that Translational Research has published data highlighting the differentiated mechanism of action of ZyVersa's Inflammasome ASC Inhibitor, IC 100. This research was conducted by renown
- PR Newswire
ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp.
ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address unmet medical needs in the areas of renal and inflammatory diseases, and Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company, announced today that they have entered into a definitive business combination agreement (the "Business Combination Agreement"). Th
